US 20130209406A1
· Tenoever
· 2013
[cited by applicant]
US 20190076460A1
· Ding
· 2019
[cited by applicant]
US 20210324014A1
· McFadden et al.
· 2021
[cited by applicant]
CN 104093830A
· 2014
[cited by applicant]
CN 110050062A
· 2019
[cited by applicant]
EP 0972840B1
· 2004
[cited by applicant]
WO WO2007143545A2
· 2007
[cited by applicant]
WO WO2015078856A1
· 2015
[cited by applicant]
WO WO2020014670A1
· 2020
[cited by applicant]
WO WO2020033510A1
· 2020
[cited by applicant]
WO WO2020037206A1
· 2020
[cited by applicant]
WO WO2020051248A1
· 2020
[cited by applicant]
WO WO2020198690A1
· 2020
[cited by applicant]
WO WO2021046048A1
· 2021
[cited by applicant]
WO WO2021046125A1
· 2021
[cited by applicant]
WO WO2022187148A2
· 2022
[cited by applicant]
Balkwill. Tumour necrosis factor and cancer. Nat Rev Cancer 9(5):361-371 (2009).
[cited by applicant]
Barrett et al. M135R is a Novel Cell Surface Virulence Factor of Myxoma Virus. Journal of Virology 81(1):106-114 (2007).
[cited by applicant]
Bartee et al., Selective purging of human multiple myeloma cells from autologous stem cell transplant grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant 18(10):1540-1551 (2012).
[cited by applicant]
Bartee et al. The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts. Journal of virology 83:498-511 (2009).
[cited by applicant]
Burton et al. Targeting TNF-alpha for cancer therapy. J Biol 8:85 (2009).
[cited by applicant]
Cameron et al., The complete DNA sequence of myxoma virus. Virology 264(2):298-318 (1999).
[cited by applicant]
Chan et al., Oncolytic Myxoma Virus: The path to clinic. Vaccine 31(39):4252-4258 (2013).
[cited by applicant]
Chan et al., Oncolytic Poxviruses. Annu Rev Virol 1(1):119-141 (2014).
[cited by applicant]
Choi et al., Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF. Gene Ther 19(7):711-723 (2012).
[cited by applicant]
Coley. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105:487-511 (1893).
[cited by applicant]
Collin et al., The poxviral scrapin MV-LAP requires a myxoma viral infection context to efficiently downregulate MHC-I molecules. Virology 343(2):171-178 (2005).
[cited by applicant]
Colombo et al. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13(2):155-168 (2002).
[cited by applicant]
Dai et al.: Myxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-dependent pathway. J Virol. 85(20):10814-10825 (2011).
[cited by applicant]
Del Vecchio et al., Interleukin-12: biological properties and clinical application. Clin Cancer Res 13(16):4677-4685 (2007).
[cited by applicant]
GenBank Accession No. AF170726.2 (2019).
[cited by applicant]
GenBank Accession No. EU552530 (2019).
[cited by applicant]
GenBank Accession No. EU552531 (2019).
[cited by applicant]
Guerin et al., Myxoma Virus Leukemia-Associated Protein is Responsible for Major Histocompatibility Complex Class I and Fas-CD95 Down-Regulation and Defines Scrapins, a New Group of Surface Cellular Receptor Abductor Pr…
[cited by applicant]
Harrington et al., Optimizing Oncolytic Virotherapy in Cancer Treatment. Nat. Reviews Drug Discovery 19:689-706 (2019).
[cited by applicant]
Hess et al., Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model. Cancer Gene Ther 8(5):371-377 (2001).
[cited by applicant]
Kashii et al., Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol 163(10):5358-5366 (1999).
[cited by applicant]
Kelly et al. History of oncolytic viruses: genesis to genetic engineering. Molecular Therapy 15:651-659 (2007).
[cited by applicant]
Kim et al., Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia 23(12):2313-2317 (2009).
[cited by applicant]
Laverty et al., TGF-beta3 and cancer: a review. Cytokine Growth Factor Rev 20(4):305-317 (2009).
[cited by applicant]
Lichty et al. Going viral with cancer immunotherapy. Nature Reviews Cancer 14:559-567 (2014).
[cited by applicant]
Lilly et al., Ex vivo oncolytic virotherapy with myxoma virus arms multiple allogeneic bone marrow transplant leukocytes to enhance graft versus tumor. Molecular Therapy Oncolytics 4:31-40 (2016).
[cited by applicant]
Liu et al. Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. J Virol. 83(11):5933-5938 (2009).
[cited by applicant]
Liu et al., The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics. Microbes Infect 12(14-15):1144-1152 (2010).
[cited by applicant]
Mansouri et al., The PHD/LAP-Domain Protein M153R of Myxomavirus Is a Ubiquitin Ligase That Induces the Rapid Internalization and Lysosomal Destruction of CD4. J Virol 77(2): 1427-1440 (2003).
[cited by applicant]
Moriwaki et al., Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. Cell Death Dis 6(2):e1636 (2015).
[cited by applicant]
Mossman et al. Myxoma virus M-T7, a secreted homolog of the interferon-gamma receptor, is a critical virulence factor for the development of myxomatosis in European rabbits. Virology 215:17-30 (1996).
[cited by applicant]
Nayerossadat et al. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res 1:27 (2012).
[cited by applicant]
Neill et al., Decorin as a multivalent therapeutic agent against cancer. Adv Drug Deliv Rev 97:174-185 (2016).
[cited by applicant]
Ogbomo et al., Myxoma Virus Infection Promotes NK Lysis of Malignant Gliomas In Vitro and In Vivo. PLoS One 8(6): e66825 (2013).
[cited by applicant]
PCT/US2019/041700 International Search Report and Written Opinion dated Nov. 12, 2019.
[cited by applicant]
PCT/US2020/049061 International Search Report and Written Opinion dated Dec. 7, 2020.
[cited by applicant]
PCT/US2020/055083 International Search Report and Written Opinion dated Jan. 26, 2021.
[cited by applicant]
PCT/US2022/018164 International Invitation to Pay Additional Fees dated Jun. 7, 2022.
[cited by applicant]
PCT/US2022/018164 International Search Report and Written Opinion dated Sep. 6, 2022.
[cited by applicant]
Prevost-Blondel et al., Crucial Role of TNF-α in CD8 T Cell-Mediated Elimination of 3LL-A9 Lewis Lung Carcinoma Cells In Vivo. J Immunol 164(7):3645-3651 (2000).
[cited by applicant]
Rahman et al., Methods for Identifying Virus-Derived Serpins: Methods and Protocols. Methods in molecular biology 1826:73-86 (2018).
[cited by applicant]
Russell et al. Oncolytic virotherapy. Nature Biotechn 30:658-670 (2012).
[cited by applicant]
Stanford et al., Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther 7(9):1415-1425 (2007).
[cited by applicant]
Stanford et al., Myxoma Virus Expressing Human Interleukin-12 Does Not Induce Myxomatosis in European Rabbits. Journal of Virology 81(22):12704-12708 (2007).
[cited by applicant]
Sypula et al., Myxoma virus tropism in human tumor cells. Gene therapy & molecular biology 8:103-114 (2004).
[cited by applicant]
U.S. Appl. No. 17/010,711 Office Action dated Dec. 24, 2020.
[cited by applicant]
U.S. Appl. No. 17/357,624 Office Action dated Mar. 21, 2022.
[cited by applicant]
U.S. Appl. No. 17/357,624 Office Action dated Nov. 12, 2021.
[cited by applicant]
Villa et al., Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. Blood 125(24): 3778-3788 (2015).
[cited by applicant]
Wang et al., Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. PNAS 103(12):4640-4645 (2006).
[cited by applicant]
Wang et al. RIG-I Mediates the Co-Induction of Tumor Necrosis Factor and Type I Interferon Elicited by Myxoma Virus in Primary Human Macrophages. PLoS Pathog 4(7):e1000099 (2008).
[cited by applicant]
Xu et al., The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther 22(3):247-256 (2015).
[cited by applicant]
Yao et al., Decorin-mediated inhibition of the migration of U87MG glioma cells involves activation of autophagy and suppression of TGF-β signaling. FEBS Open Bio 6(7):707-719 (2016).
[cited by applicant]
Yu et al. Targeting Transmembrane TNF-a Suppresses Breast Cancer Growth. Cancer Res 73(13):4061-4075 (2013).
[cited by applicant]
Zhang et al., Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther 19(8):1558-1568 (2011).
[cited by applicant]